RxDoctor Payments Data

Jonathan Sher

Corneal and Contact Management · McKinney, TXNPI 1730171422

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.4% of the total. Reporting peaked in 2022 at $626 and has fallen 85.0% since, to $94 in 2025.

$1,617in general payments, 2019–2025

Across 34 payments — averaging $47.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$426
  • Heru, Inc.$355
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$294
  • Alcon$221
  • Coopervision Inc.$213
  • Carl Zeiss Meditec USA, Inc.$32
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$1,59799%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,617 in reported general payments places this provider in the 60th percentile of 103 corneal and contact management providers in Texas.

See all corneal and contact management providers in Texas

Medicare billing

Part B allowed, 2024
$22,531
Medicare patients
140
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost15$7,019
Travoprost37$5,659
Brimonidine Tartrate38$1,748
Latanoprost53$319

Paid to pharmacies, not to this prescriber.

Other corneal and contact management in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →